Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 79,340,272
  • Shares Outstanding, K 105,099
  • Annual Sales, $ 14,343 M
  • Annual Income, $ 4,505 M
  • EBIT $ 3,578 M
  • EBITDA $ 4,122 M
  • 60-Month Beta 0.40
  • Price/Sales 5.72
  • Price/Cash Flow 18.48
  • Price/Book 2.62

Options Overview Details

View History
  • Implied Volatility 33.41% (-2.68%)
  • Historical Volatility 29.12%
  • IV Percentile 24%
  • IV Rank 21.28%
  • IV High 60.01% on 04/08/25
  • IV Low 26.22% on 11/26/25
  • Expected Move (DTE 2) 29.41 (3.78%)
  • Put/Call Vol Ratio 0.45
  • Today's Volume 1,124
  • Volume Avg (30-Day) 2,045
  • Put/Call OI Ratio 0.66
  • Today's Open Interest 46,798
  • Open Int (30-Day) 47,633
  • Expected Range 749.56 to 808.38

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 27 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 5.96
  • Number of Estimates 6
  • High Estimate 8.00
  • Low Estimate 4.29
  • Prior Year 6.43
  • Growth Rate Est. (year over year) -7.31%

Price Performance

See More
Period Period Low Period High Performance
1-Month
718.38 +8.43%
on 01/20/26
811.09 -3.96%
on 01/12/26
-17.58 (-2.21%)
since 01/09/26
3-Month
672.67 +15.80%
on 11/12/25
821.11 -5.13%
on 01/09/26
+104.42 (+15.48%)
since 11/11/25
52-Week
476.49 +63.48%
on 06/05/25
821.11 -5.13%
on 01/09/26
+113.51 (+17.06%)
since 02/11/25

Most Recent Stories

More News
Regeneron Announces Investor Conference Presentations

TARRYTOWN, N.Y., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:  REGN ) will webcast management participation as follows: TD Cowen 46th Annual Health Care Conference...

REGN : 778.97 (+3.19%)
Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy

36 abstracts to be presented across Regeneron-invented therapies, including first-time Phase 3 presentations for two distinct investigational allergen-blocking antibodies for cat and birch allergies ...

REGN : 778.97 (+3.19%)
EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases

TARRYTOWN, N.Y., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced upcoming presentations from its ophthalmology portfolio and pipeline at the virtual Angiogenesis...

REGN : 778.97 (+3.19%)
Regeneron: Q4 Earnings Snapshot

Regeneron: Q4 Earnings Snapshot

REGN : 778.97 (+3.19%)
Regeneron (NASDAQ:REGN) Posts Better-Than-Expected Sales In Q4 CY2025

Regeneron (NASDAQ:REGN) Posts Better-Than-Expected Sales In Q4 CY2025

REGN : 778.97 (+3.19%)
Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Fourth quarter 2025 revenues increased 3% to $3.9 billion versus fourth quarter 2024; full year 2025 revenues increased 1% to $14.3 billion versus 2024 Fourth quarter 2025 Dupixent ® global...

REGN : 778.97 (+3.19%)
Earnings To Watch: Regeneron (REGN) Reports Q4 Results Tomorrow

Earnings To Watch: Regeneron (REGN) Reports Q4 Results Tomorrow

REGN : 778.97 (+3.19%)
Nation’s Top 40 High School Scientists to Compete for $1.8 Million in Awards at the Prestigious Regeneron Science Talent Search

TARRYTOWN N.Y. and WASHINGTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Society for Science (the Society) and Regeneron today announced the top 40 finalists in the Regeneron Science Talent Search 2026,...

REGN : 778.97 (+3.19%)
Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All

As weight loss drugs move from injections to pills, this thematic ETF provides broad exposure for investors looking to profit from the industry’s next leg up.

VKTX : 28.55 (-0.70%)
AZN : 204.76 (+5.87%)
OZEM : 35.60 (-0.01%)
NVO : 48.74 (-0.77%)
LLY : 1,015.21 (-0.96%)
REGN : 778.97 (+3.19%)
AMGN : 366.58 (+0.53%)
PFE : 27.73 (+0.43%)
3 Profitable Stocks We Think Twice About

3 Profitable Stocks We Think Twice About

REGN : 778.97 (+3.19%)
CVGW : 25.09 (unch)
LAD : 320.41 (-1.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also...

See More

Key Turning Points

3rd Resistance Point 828.25
2nd Resistance Point 804.84
1st Resistance Point 791.90
Last Price 778.97
1st Support Level 755.55
2nd Support Level 732.14
3rd Support Level 719.21

See More

52-Week High 821.11
Last Price 778.97
Fibonacci 61.8% 689.46
Fibonacci 50% 648.80
Fibonacci 38.2% 608.13
52-Week Low 476.49

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar